scPharmaceuticals Inc (SCPH) Actualités

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include...

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a...

Form 4 - Statement of changes in beneficial ownership of securities

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a...

Form 8-K - Current report

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3...

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report